Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyHealthfirst Pathogen Panel Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedHealthfirstPolicy PO-RE-012v8

    Pathogen Panel Testing

    Customize your policy alerts

    Sign up for Healthfirst Policy PO-RE-012v8 alerts

    Get alerted when Policy PO-RE-012v8 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs outpatient coverage for gastrointestinal, respiratory, cerebrospinal fluid, blood, urine, wound, joint, and general microorganism pathogen panel testing. Coverage depends on the clinical indication, patient symptoms or immune status, specimen source, panel size, and testing frequency.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerHealthfirst
    PolicyPathogen Panel Testing
    Policy CodePolicy PO-RE-012v8
    Change TypeModified
    Effective DateNovember 1, 2026
    Last ReviewJun 3, 2026
    Next Review DateN/A
    Key ActionDocument the clinical features supporting gastrointestinal pathogen testing, including relevant symptoms, risk factors, exposures, or signs of severe disease.
    SourceLink
    POLICY UPDATE CHANGES

    The June 3, 2026 review updated the background, guidelines, evidence-based references, and edited coverage criteria CC1, CC2, and CC5 for consistency.

    Effective December 3, 2025, new coverage criterion CC10 states that molecular-based panel testing to screen for or diagnose joint infections does not meet coverage criteria.

    Effective January 1, 2026, CPT code 87627 and codes 0601U were added.

    CPT codes 0441U and 0442U were removed effective December 3, 2025.

    Effective January 1, 2026, CPT code 87812 and codes 0600U and 0610U were added through an off-cycle coding modification.

    New CC3 provides coverage for immunocompromised individuals with signs and symptoms of respiratory tract infection when multiplex PCR-based testing evaluates up to 25 respiratory pathogens.

    CC5 was revised to state that, for situations not otherwise described, antigen panel testing or multiplex PCR-based testing of 6 or more respiratory pathogens does not meet coverage criteria.

    CC2 was revised to cover antigen or multiplex PCR-based panel testing of up to 5 respiratory pathogens for individuals displaying signs and symptoms of respiratory tract infection.

    CC4 was revised to include antigen panel testing in the noncoverage criterion for testing 6 or more respiratory pathogens.

    Note 1 added adult and pediatric signs and symptoms of respiratory tract infection, including nonspecific infant presentations.

    CPT code 87428 and codes 0556U, 0563U, and 0564U were added effective July 1, 2025.

    CPT codes 0240U, 0241U, 0369U, 0370U, 0373U, and 0374U were removed as deleted codes effective July 1, 2025.

    Up to 11 GIPsCovered gastrointestinal panel size
    Every 7 daysGastrointestinal testing frequency
    Up to 5Covered respiratory panel size
    Up to 25Covered immunocompromised respiratory panel size
    12+ GIPsNoncovered gastrointestinal panel threshold
    6+ pathogensNoncovered respiratory panel threshold

    Coverage Criteria

    Gastrointestinal pathogen panel testing

    Covered when all applicable conditions are met.

    Qualifying gastrointestinal pathogen testing

    • Gastrointestinal clinical indication

      • Persistent diarrhea is present.
      • Diarrhea is accompanied by signs or risk factors for severe disease, such as fever, bloody diarrhea, dysentery, dehydration, or severe abdominal pain.
    • Panel and frequency limit: Multiplex PCR-based panel contains up to 11 gastrointestinal pathogens and is performed no more often than once every seven days.Up to 11 pathogens; once every 7 days

    Respiratory pathogen panel testing

    Covered when all applicable conditions are met.

    Respiratory panel testing

    • Clinical indication: Signs or symptoms of respiratory tract infection are present, including fever, chills, fatigue, cough, rhinorrhea, pharyngitis, vomiting, new loss of taste or smell, headache, myalgia, diarrhea, weakness, or applicable pediatric or infant findings.
    • Test type and panel size: Testing uses an antigen panel or multiplex PCR-based panel and includes no more than five respiratory pathogens.Up to 5 pathogens

    Respiratory panel testing in immunocompromised individuals

    Covered when all applicable conditions are met.

    Expanded respiratory testing for immunocompromised individuals

    • Immune status and symptoms: The individual is immunocompromised and has signs or symptoms of respiratory tract infection.
    • Test type and panel size: Testing is multiplex PCR-based and includes no more than 25 respiratory pathogens.Up to 25 pathogens

    Noncovered pathogen panel testing

    Does not meet coverage criteria.

    • Multiplex PCR-based panel testing includes 12 or more gastrointestinal pathogens.12 or more GIPs
    • Antigen or multiplex PCR-based panel testing includes six or more respiratory pathogens and the situation is not otherwise described as covered.6 or more respiratory pathogens
    • Multiplex PCR-based panel testing is performed for pathogens in cerebrospinal fluid.
    • Molecular detection-based panel testing is performed for pathogens in blood.
    • Molecular detection-based panel testing is used for urine pathogens in diagnosing urinary tract infection, wound infection, joint infection, or general microorganism screening.

    Gastrointestinal testing indications

    Gastrointestinal pathogen testing is medically necessary when at least one qualifying clinical context is present.

    Qualifying gastrointestinal indication

    • Clinical severity or presentation

      • Moderate-to-severe diarrhea, bloody or mucoid stools, fever, dysentery, severe abdominal cramping or tenderness, persistent diarrhea, or signs of sepsis are present.
    • Risk or exposure context

      • The patient is immunocompromised, has a suspected outbreak or nosocomial exposure, or has travel, parasitic-exposure, or other risk factors supporting pathogen identification.

    Selection of gastrointestinal molecular testing

    When gastrointestinal testing is clinically appropriate, the selected test should match the suspected pathogen group and clinical context.

    Appropriate gastrointestinal molecular testing

    • Pathogen group and clinical context

      • The testing approach addresses suspected bacterial, viral, or parasitic gastroenteritis based on symptoms, duration, exposures, and patient risk.
      • Symptoms persist beyond seven days, the initial evaluation is inconclusive, or the patient has risk factors for parasitic disease.>7 days for persistent diarrhea when considering parasitic testing

    Clostridioides difficile testing

    C. difficile testing should be performed only in symptomatic patients and interpreted using an appropriate testing algorithm.

    C. difficile diagnostic testing

    • Active compatible symptoms: The patient has diarrhea or at least three unformed stools in 24 hours and symptoms suggest active C. difficile infection.3 or more unformed stools in 24 hours

      Do not test formed stool or asymptomatic patients.

    • Acceptable multistep algorithm

      • Testing uses GDH plus toxin.
      • Testing uses GDH plus toxin, arbitrated by NAAT.

    Symptomatic respiratory infection testing

    Covered when the individual displays signs and symptoms of a respiratory tract infection.

    Symptomatic respiratory infection panel: Panel testing of up to five respiratory pathogens using antigen panel testing or multiplex PCR-based panel testing meets coverage criteria.Up to 5 respiratory pathogens

    The individual must display signs and symptoms of respiratory tract infection.

    Immunocompromised individuals

    Covered when the individual is immunocompromised and displays signs and symptoms of a respiratory tract infection.

    Immunocompromised respiratory infection panel: Multiplex PCR-based panel testing of up to 25 respiratory pathogens meets coverage criteria.Up to 25 respiratory pathogens

    Respiratory tract infection signs and symptoms are described in Note 1.

    Respiratory panels of 6 or more pathogens

    Not covered for situations not otherwise described.

    Large respiratory pathogen panels: Antigen panel testing or multiplex PCR-based panel testing of six or more respiratory pathogens does not meet coverage criteria.6 or more respiratory pathogens

    An exception applies when a separate covered indication, such as the immunocompromised-patient criterion, applies.

    Joint infection testing

    Does not meet coverage criteria.

    Joint infection molecular panels: Molecular-based panel testing to screen for or diagnose joint infections does not meet coverage criteria.

    Examples include the BIOFIRE Joint Infection Panel and Synovasure Comprehensive PJI Test Panel with SynTuition.

    These coverage criteria apply only to outpatient testing; they do not apply to testing allowances in other care settings. Coverage is assessed based on the clinical indication, specimen source, panel size, and testing frequency.

    Molecular pathogen panel testing of cerebrospinal fluid, blood, urine for urinary tract infection, wounds, joints, or for general microorganism screening does not meet coverage criteria.

    Routine gastrointestinal pathogen testing is not recommended for non-inflammatory, self-limited diarrhea or short-duration acute gastroenteritis when relevant risk factors or clinical features supporting diagnostic testing are absent.

    Repeat C. difficile testing within seven days should not be performed, and testing for cure after treatment is not recommended. Testing should be limited to individuals with symptoms suggestive of active infection and interpreted using an appropriate multistep algorithm.

    Molecular-based panel testing used to screen for or diagnose joint infections does not meet coverage criteria. Examples include the BIOFIRE Joint Infection Panel and Synovasure Comprehensive PJI Test Panel with SynTuition.

    For situations not otherwise described as covered, antigen or multiplex PCR-based respiratory panels evaluating 6 or more pathogens do not meet coverage criteria. Expanded respiratory testing may qualify when a separate covered indication applies, such as symptomatic respiratory infection in an immunocompromised individual.

    The policy does not cover molecular pathogen panels for urine-based urinary tract infection testing, wound or joint infection screening or diagnosis, or general microorganism screening. Molecular panel testing of cerebrospinal fluid and blood also does not meet coverage criteria.

    Multiplex gastrointestinal testing may have limited clinical utility in an immunocompetent individual with likely uncomplicated viral gastroenteritis, particularly when the result is unlikely to change clinical management.

    Covered Clinical Indications

    Persistent diarrhea or diarrhea with severe-disease signs or risk factors

    Covered when all applicable conditions are met.

    Qualifying gastrointestinal panel

    • Qualifying diarrhea presentation

      • Persistent diarrhea is present.
      • Diarrhea is accompanied by fever, bloody diarrhea, dysentery, dehydration, or severe abdominal pain.
    • Testing is performed no more often than once every seven days.Once every 7 days

    Signs and symptoms of respiratory tract infection

    Testing Frequency Limits

    Frequency limits
    Panel typeMultiplex PCR-based gastrointestinal pathogen panel
    Maximum panel sizeUp to 11 gastrointestinal pathogens
    Frequency limitNo more often than once every seven days
    C. difficile frequency limits
    Test populationIndividuals with symptoms suggestive of active Clostridioides difficile infection
    Repeat testingDo not repeat C. difficile testing within seven days
    Test of cureDo not perform testing for cure

    Applicable Codes and Coding Parameters

    Applicable CodesCPT
    87154Culture, typing; identification of blood pathogen and resistance typing, when performed, by nucleic acid (DNA or RNA) probe, multiplexed amplified probe technique including multiplex reverse transcription, when performed, per culture or isolate, 6 or more targets.
    87428Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B.
    Applicable CPT and molecular pathogen panel codesCPT
    87154Culture, typing; identification of blood pathogen and resistance typing, when performed, by nucleic acid (DNA or RNA) probe, multiplexed amplified probe technique including multiplex reverse transcription, when performed, per culture or isolate, 6 or more targets.
    87428Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B.
    Applicable pathogen panel codes and descriptionsCPT
    87428Infectious agent detection by nucleic acid (DNA or RNA); central nervous system pathogen, including multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.
    87428Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen, including multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
    87428Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen, including multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
    87428Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen, including multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.
    87428Infectious agent detection by nucleic acid (DNA or RNA); joint space pathogens and drug resistance genes, multiplex amplified probe technique, 26 or more targets.
    87428Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, including multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
    87428Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, including multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
    87428Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, including multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.
    87428Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus types A and B, multiplex amplified probe technique.
    87428Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique.
    1–10 of 12
    1/2
    Applicable Proprietary Laboratory Analysis codesHCPCS
    0086UInfectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based.
    0109UInfectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (A. fumigatus, A. terreus, A. niger, and A. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species.
    0202UInfectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
    0480UInfectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic next-generation sequencing (DNA and RNA), bioinformatic analysis, with positive pathogen identification.
    0504UPathologic organisms, urine, realtime PCR, reported as positive or negative for each organism.
    0528ULower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 anti-microbial resistance genes, amplified probe technique, including reverse transcription for RNA targets, each analyte reported as detected or not detected with semiquantitative results for 15 bacteria.
    0531UInfectious disease (acid-fast bacteria and invasive fungi), DNA (673 organisms), next-generation sequencing, plasma.
    0556UInfectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
    0563UInfectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
    0563UInfectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
    Added codes effective December 3, 2025mixed
    87627Added CPT code
    0601UAdded code
    Removed codesmixedNot Covered
    0441URemoved CPT code
    0442URemoved code
    Off-cycle coding additions effective January 1, 2026mixed
    87812Added CPT code effective January 1, 2026
    0600UAdded code effective January 1, 2026
    0610UAdded code effective January 1, 2026
    Added codes effective July 1, 2025mixed
    87428Added CPT code effective July 1, 2025
    0556UAdded code effective July 1, 2025
    0563UAdded code effective July 1, 2025
    0564UAdded code effective July 1, 2025
    Deleted codes removed effective July 1, 2025HCPCSNot Covered
    0240UDeleted code removed effective July 1, 2025
    0241UDeleted code removed effective July 1, 2025
    0369UDeleted code removed effective July 1, 2025
    0370UDeleted code removed effective July 1, 2025
    0373UDeleted code removed effective July 1, 2025
    0374UDeleted code removed effective July 1, 2025
    Additional off-cycle coding additionsHCPCS
    0531UAdded code effective April 1, 2025
    0202UAdded code
    0223UAdded code
    0225UAdded code
    0528UAdded new code effective January 1, 2025
    Qualifying gastrointestinal panel
    Covered indicationPersistent diarrhea or diarrhea with signs or risk factors for severe disease
    Panel sizeUp to 11 gastrointestinal pathogens
    Testing frequencyNo more often than once every seven days
    Qualifying respiratory panel
    Covered indicationSigns and symptoms of a respiratory tract infection

    Provider Documentation and Denial Risks

    Documentation Required

    Document Clinical Indication and Risk Factors

    Document persistent diarrhea or diarrhea with severe-disease signs or risk factors before ordering gastrointestinal multiplex PCR testing. Qualifying findings include fever, bloody diarrhea or dysentery, dehydration, severe abdominal pain, immunocompromise, relevant exposure risk, or persistent symptoms; testing is limited to no more than once every seven days.

    • Record the patient's symptoms, duration, severity, risk factors, and relevant exposure history.
    • Use multiplex gastrointestinal panel testing only when the clinical context supports medical necessity and within the 11-pathogen limit.
    Documentation Required

    Document Active C. difficile Symptoms and Testing Algorithm

    For suspected C. difficile infection, test only patients with symptoms of active infection and use an appropriate multistep algorithm. Document at least three unformed stools in 24 hours, or other clinically relevant active symptoms, and pair a highly sensitive test with a highly specific modality rather than relying on NAAT or GDH alone.

    Background

    Multiplex molecular panels can rapidly detect multiple bacterial, viral, and parasitic pathogens from a single specimen and may provide more sensitive detection than culture or antigen testing. However, broad panels may identify colonizing organisms, prolonged shedding, or co-infections of uncertain clinical significance, which can lead to unnecessary treatment and cost. Targeted testing is generally favored for immunocompetent patients with mild or moderate respiratory illness, while expanded testing may be useful for selected immunocompromised or critically ill patients.

    Definitions

    Definitions
    PurposeSimultaneously detects multiple pathogens from a single sample
    TechniquesMultiplex amplified probe techniques or multiplex reverse transcription
    Pathogens detectedMay include bacterial, viral, and parasitic pathogens
    Definitions
    MeaningA group of pathogens associated with gastrointestinal illness and diarrheal disease
    Pathogen typesBacterial, viral, protozoal, and parasitic agents
    Clinical presentationsMay range from self-limited, non-inflammatory diarrhea to severe, persistent, or febrile dysenteric illness

    Ordering Requirements

    Note

    Order and interpret testing in clinical context

    Testing should be ordered and interpreted by a clinician in the context of the patient's symptoms, exposures, risk profile, and suspected pathogen. Select the panel based on the clinical presentation, the likelihood that results will affect management, and the panel's characteristics and target list.

    • When a bacterial pathogen is detected by a culture-independent method, arrange clinical or public health laboratory culture when isolation is requested or required.
    • For hospitalized patients with acute respiratory illness, CDC guidance recommends a multiplex nucleic acid detection assay for influenza A/B/SARS-CoV-2 when available.
    • For suspected prosthetic joint infection, use synovial fluid cell count and differential, Gram stain when appropriate, and aerobic and anaerobic culture; preoperative aspiration is an acceptable source.

    Not Covered Services and Situations

    Multiplex PCR-based gastrointestinal pathogen panels containing 12 or more pathogens do not meet coverage criteria. Panels of up to 11 gastrointestinal pathogens may qualify only when the applicable clinical indication and frequency requirements are met.

    Antigen or multiplex PCR-based respiratory panels evaluating 6 or more pathogens do not meet coverage criteria for situations not otherwise described as covered. Covered situations include symptomatic respiratory infection testing of up to 5 pathogens and multiplex PCR testing of up to 25 pathogens in symptomatic immunocompromised individuals.

    Testing is not covered when molecular pathogen panels are performed on cerebrospinal fluid or blood, or when panels are used for urine-based urinary tract infection testing, wound infection screening or diagnosis, joint infection screening or diagnosis, or general microorganism screening.

    General microorganism molecular panel testing does not meet coverage criteria. The exclusion also includes molecular panels used to evaluate pathogens in blood, urine for urinary tract infection, wounds, or joints.

    Gastrointestinal pathogen testing outside qualifying clinical situations is not covered, including testing for non-inflammatory, self-limited diarrhea or short-duration acute gastroenteritis without relevant risk factors or clinical features. Testing may be appropriate for moderate-to-severe, bloody, febrile, dysenteric, persistent, or nosocomial-associated diarrhea, immunocompromised individuals, suspected outbreaks, severe abdominal symptoms, or signs of sepsis.

    Multiplex gastrointestinal panels, particularly those containing viral targets, may not be covered for uncomplicated or self-limited viral illness in an immunocompetent individual when results are unlikely to affect clinical decision-making.

    Policy Summary
    PayerHealthfirst
    PolicyPathogen Panel Testing
    Policy CodePolicy PO-RE-012v8
    Change TypeModified
    Effective DateNovember 1, 2026
    Last ReviewJun 3, 2026
    Next Review DateN/A
    Key ActionDocument the clinical features supporting gastrointestinal pathogen testing, including relevant symptoms, risk factors, exposures, or signs of severe disease.
    SourceLink
    On This Page
    Coverage CriteriaCovered Clinical IndicationsTesting Frequency LimitsApplicable Codes and Coding ParametersProvider Documentation and Denial RisksBackgroundDefinitionsOrdering RequirementsNot Covered Services and Situations
    Testing uses NAAT plus toxin.

    Covered when all applicable conditions are met.

    Respiratory panel up to five pathogens

    • Signs or symptoms are present, including fever, chills, fatigue, cough, rhinorrhea, pharyngitis, vomiting, new ageusia or anosmia, headache, myalgia, diarrhea, or weakness; pediatric and infant presentations may also qualify.

    Respiratory infection symptoms in an immunocompromised individual

    Covered when all applicable conditions are met.

    Expanded respiratory panel

    • The individual is immunocompromised and displays signs or symptoms of respiratory tract infection.
    • Testing is multiplex PCR-based and evaluates no more than 25 respiratory pathogens.Up to 25 pathogens

    Qualifying severe, inflammatory, persistent, nosocomial, immunocompromised, outbreak, or sepsis-associated diarrhea

    Testing may be used when clinically appropriate and expected to influence management.

    Qualifying gastrointestinal clinical context

    • Moderate-to-severe, bloody, febrile, dysenteric, persistent, or nosocomial-associated diarrhea is present.
    • The patient is immunocompromised and has diarrhea.
    • A suspected outbreak or relevant exposure is present.
    • Severe abdominal cramping or tenderness is present.
    • Signs of sepsis are present.

    Diarrhea lasting more than seven days or suspected parasitic disease with exposure risk

    Parasitic pathogen testing may be considered when clinically appropriate.

    Persistent or exposure-associated diarrhea: The patient has diarrhea lasting more than seven days or suspected parasitic disease with relevant exposure risk, particularly when the initial workup is inconclusive.>7 days

    Suspected active C. difficile infection in a symptomatic patient

    Use a multistep algorithm incorporating a sensitive modality and a specific toxin test.

    Suspected active C. difficile infection

    • Testing algorithm

      • Use GDH plus toxin.
      • Use GDH plus toxin, arbitrated by NAAT.
      • Use NAAT plus toxin.

    Diarrhea of unknown etiology with relevant exposure risks

    More comprehensive syndromic panels may be useful when the cause of diarrhea is unknown and testing is expected to influence management.

    Diarrhea of unknown etiology

    • Supporting clinical context

      • Fever or bloody or mucoid stools are present.
      • Severe abdominal cramping or tenderness is present.
      • Signs of sepsis are present.
      • Relevant travel, parasitic, outbreak, or other exposure risk is present.

    Severe or high-risk respiratory illness

    Panel testing is most likely to influence management in severe illness or significant risk-factor settings.

    • The patient is hospitalized or critically ill with respiratory illness.
    • The patient is immunocompromised.
    • The patient may require hospital admission or has significant risk factors.
    • Identification of a pathogen such as influenza, Legionella, or SARS-CoV-2 is expected to affect treatment or public-health management.

    Suspected enteroviral CNS infection, acute flaccid myelitis, or other CNS involvement

    CSF NAAT is recommended when these clinical concerns are present.

    Central nervous system indication

    • Enteroviral central nervous system infection is suspected.
    • The patient has signs of acute flaccid myelitis.
    • Other central nervous system involvement is present.

    Higher-risk patients evaluated for sexually transmitted infections or bacterial-vaginosis-associated organisms

    Multiplex testing may be appropriate in higher-risk patients being evaluated for these infections.

    Higher-risk genitourinary infection evaluation

    • The patient is at higher risk for sexually transmitted infections and is being evaluated for them.
    • The patient is being evaluated for bacterial-vaginosis-associated organisms.

    Critically ill patients with new fever or new upper respiratory infection symptoms

    Viral NAAT panel testing is suggested in this critically ill presentation.

    Critical illness with new fever or respiratory symptoms

    • Associated testing consideration

      • Viral pathogen testing using a viral NAAT panel is performed or considered.
      • For new fever, SARS-CoV-2 PCR testing is performed based on community transmission levels.

    Solid organ transplant recipients with suspected gastrointestinal infection

    Gastrointestinal multiplex molecular assays are recommended for suspected gastrointestinal infection in this population.

    Solid organ transplant recipient

    • Targeted pathogen evaluation

      • Testing evaluates Cryptosporidium.
      • Testing evaluates Cyclospora.
      • Testing evaluates Giardia.

    Signs and symptoms of respiratory tract infection — panel up to five pathogens

    Covered when the individual displays signs and symptoms of a respiratory tract infection.

    Respiratory panel up to five pathogens: The individual displays signs or symptoms of respiratory tract infection and receives antigen or multiplex PCR-based panel testing of up to five respiratory pathogens.Up to 5 respiratory pathogens

    Immunocompromised individuals with respiratory infection symptoms — panel up to 25 pathogens

    Covered when the individual is immunocompromised and displays signs and symptoms of a respiratory tract infection.

    Respiratory panel up to 25 pathogens: The individual is immunocompromised, displays signs or symptoms of respiratory tract infection, and receives multiplex PCR-based panel testing of up to 25 respiratory pathogens.Up to 25 respiratory pathogens
    C. difficile repeat testing
    TestClostridioides difficile testing
    Seven-day limitDo not repeat testing within seven days
    Clinical useTesting should be limited to patients with symptoms suggestive of active infection
    Panel sizeUp to 5 respiratory pathogens
    Permitted methodsAntigen panel testing or multiplex PCR-based panel testing
    Immunocompromised respiratory panel
    Covered populationImmunocompromised individuals displaying signs and symptoms of a respiratory tract infection
    Panel sizeUp to 25 respiratory pathogens by multiplex PCR
    SettingOutpatient testing
    Noncovered gastrointestinal panel
    Test typeMultiplex PCR-based gastrointestinal pathogen panel
    Noncovered threshold12 or more gastrointestinal pathogens
    Coverage statusDoes not meet coverage criteria
    Noncovered respiratory panel
    Test typeAntigen panel testing or multiplex PCR-based respiratory panel testing
    Noncovered threshold6 or more respiratory pathogens
    QualificationApplies when the situation is not otherwise described as covered
    Gastrointestinal testing frequency
    TestMultiplex PCR-based gastrointestinal pathogen panel of up to 11 pathogens
    Frequency limitNo more often than once every seven days
    Coverage contextApplies to qualifying persistent diarrhea or diarrhea with signs or risk factors for severe disease
    Blood pathogen identification and resistance typing
    Code87154
    TestIdentification of blood pathogen and resistance typing by multiplex amplified probe technique
    Target threshold6 or more targets
    Central nervous system pathogen testing
    TestCentral nervous system pathogen detection by nucleic acid testing
    MethodMultiplex reverse transcription and multiplex amplified probe technique
    Target range12-25 targets
    Gastrointestinal pathogen multiplex testing
    TestGastrointestinal pathogen detection by nucleic acid testing
    MethodMultiplex reverse transcription and multiplex amplified probe technique
    Target range3-5 targets
    Blood pathogen and resistance typing
    TestBlood pathogen identification and resistance typing
    MethodNucleic acid probe using multiplex amplified probe technique, including multiplex reverse transcription when performed
    Target threshold6 or more targets
    Central nervous system pathogen panel
    TestCentral nervous system pathogen panel
    Detection methodNucleic acid detection with multiplex reverse transcription and multiplex amplified probe technique
    Target range12-25 targets
    Gastrointestinal pathogen panel
    TestGastrointestinal pathogen nucleic acid panel
    Target ranges3-5, 6-11, or 12-25 targets
    MethodMultiplex reverse transcription and multiplex amplified probe technique
    Joint space pathogen panel
    TestJoint space pathogen and drug-resistance gene panel
    MethodMultiplex amplified probe technique
    Target threshold26 or more targets
    Respiratory virus panel
    TestRespiratory virus nucleic acid panel
    MethodMultiplex reverse transcription and multiplex amplified probe technique
    Target ranges3-5, 6-11, or 12-25 targets
    Fungal/AFB sequencing assay
    TestFungal and acid-fast bacteria infectious disease assay
    MethodNext-generation sequencing
    Organism countDNA from 673 organisms
    General symptomatic respiratory infection panel
    Covered populationIndividuals displaying signs and symptoms of a respiratory tract infection
    Panel sizeUp to 5 respiratory pathogens
    Permitted methodsAntigen panel testing or multiplex PCR-based panel testing
    Immunocompromised respiratory infection panel
    Covered populationImmunocompromised individuals displaying signs and symptoms of a respiratory tract infection
    Panel sizeUp to 25 respiratory pathogens
    MethodMultiplex PCR-based panel testing
    Respiratory panel noncoverage
    Test typesAntigen panel testing or multiplex PCR-based respiratory panel testing
    Noncoverage threshold6 or more respiratory pathogens
    ExceptionDoes not apply when a separate covered indication, such as the immunocompromised-patient criterion, applies
  1. Document active symptoms, including three or more unformed stools in 24 hours when applicable.
  2. Use a two-step or multistep algorithm such as GDH plus toxin, GDH plus toxin arbitrated by NAAT, or NAAT plus toxin.
  3. Interpret positive molecular results in the context of the clinical presentation because NAAT detects DNA and may identify colonization.
  4. Documentation Required

    Consider Follow-up Culture

    When a culture-independent test identifies a bacterial pathogen, arrange confirmatory culture when isolation is requested or required by clinical or public-health considerations. Document the rationale for follow-up culture and the intended use of the result.

    • Consider culture after a positive antigen-based or molecular result when organism isolation is needed.
    • Follow applicable clinical laboratory and public-health reporting requirements.
    Denial Risk

    Testing Outside Covered Outpatient Indications

    Do not assume coverage for testing performed outside the defined outpatient indications. Gastrointestinal testing is supported for persistent or moderate-to-severe diarrhea, severe-disease features, relevant exposure or risk factors, or immunocompromise; respiratory testing requires respiratory symptoms and is subject to pathogen-count limits.

    • Apply the policy's outpatient criteria and verify the member's benefit coverage.
    • Testing in settings or clinical situations not described by the policy may not meet coverage criteria.
    Denial Risk

    Excluded Specimen Sources and Uses

    Do not use pathogen panels for excluded specimen sources or noncovered screening purposes. Panel testing of pathogens in cerebrospinal fluid or blood, and molecular panels for urine, wound, joint infection, or general microorganism screening, do not meet coverage criteria under this policy.

    • CSF pathogen panels: does not meet coverage criteria.
    • Blood pathogen molecular panels: does not meet coverage criteria.
    • Urine, wound, joint-infection, and general microorganism screening panels: does not meet coverage criteria.
    Denial Risk

    Use Testing for Medically Appropriate Gastrointestinal Indications

    Order gastrointestinal pathogen testing only when it is medically appropriate for the patient's presentation and likely to affect management. Testing is generally supported for moderate-to-severe, bloody, febrile, dysenteric, persistent, or nosocomial diarrhea, immunocompromise, or relevant exposure risk.

    • Consider parasitic testing for diarrhea lasting more than seven days when initial evaluation is inconclusive and exposure risk is present.
    • Interpret highly multiplexed results in light of the patient's clinical presentation and risk profile.
    Denial Risk

    Avoid Low-Utility Testing in Uncomplicated Viral Illness

    Avoid low-utility gastrointestinal panel testing in uncomplicated, short-duration, noninflammatory, self-limited diarrhea or likely viral gastroenteritis in an immunocompetent patient. Such testing often does not change management and may lead to unnecessary downstream interventions.

    • Document an appropriate clinical indication before ordering a panel.
    • Do not order broad testing solely for uncomplicated viral illness without qualifying symptoms or risk factors.
    Denial Risk

    Do Not Repeat or Perform Test-of-Cure C. difficile Testing

    Do not repeat C. difficile testing within seven days or perform testing to document cure. Repeat testing and test-of-cure testing are discouraged because results may not distinguish ongoing disease from colonization or residual nucleic acid.

    • Do not repeat a C. difficile test within seven days.
    • Do not perform post-treatment test-of-cure testing.
    • Reevaluate the patient clinically and test again only when a new, appropriate episode of active symptoms meets testing criteria.
    Denial Risk

    Panel Exceeds Respiratory Pathogen Limit

    Respiratory antigen or multiplex PCR panel testing is covered for up to five pathogens when the patient has signs and symptoms of respiratory tract infection. Testing of six or more pathogens generally does not meet coverage criteria, except that immunocompromised patients with qualifying respiratory symptoms may meet criteria for multiplex PCR testing of up to 25 pathogens.

    • Document qualifying respiratory signs and symptoms.
    • For immunocompromised patients, document the immune status and respiratory symptoms supporting the up-to-25-pathogen exception.
    • Panels of 12 or more gastrointestinal pathogens do not meet coverage criteria.
    Denial Risk

    Joint Infection Molecular Panels Are Not Covered

    Molecular panel testing for joint infections does not meet coverage criteria, including the BIOFIRE Joint Infection Panel and Synovasure Comprehensive PJI Test Panel with SynTuition.

    • Do not submit joint-infection molecular panels as covered services under this policy.
    • Coverage criteria do not change based solely on the named commercial panel.
    Billing Rule

    Coding and Billing Compliance

    Follow Healthfirst, CMS, NCCI, AMA, ICD-10, revenue-code, modifier, and applicable New York State coding and billing requirements. Failure to follow applicable coding, billing, or reimbursement guidelines may result in claim denial or recoupment.

    • Use current, accurate codes and appropriate modifiers for the service performed.
    • Check duplicate, medically unlikely, multiple-procedure, global-surgery, and other applicable claim edits.
    • Coverage and payment remain subject to the member's benefit, applicable law, participation agreement, and Healthfirst claim review.
    Definitions
    Common adult symptomsFever, chills, fatigue, cough, rhinorrhea, anorexia, pharyngitis, vomiting, new ageusia or anosmia, headaches, myalgia, diarrhea, and weakness
    Pediatric symptomsMay include irritability, decreased activity, nausea, rash, stomach pain, tachypnea, wheezing, dehydration, cyanosis, or apnea
    Infant presentationsPoor feeding, lethargy, and fussiness may occur without clear localizing symptoms
    Definitions
    MeaningA test that detects pathogen-associated nucleic acid or other targets without requiring growth in culture
    ExamplesMultiplex molecular panels and nucleic acid amplification tests
    Clinical useCan detect bacterial, viral, and parasitic causes of gastroenteritis
    Definitions
    MeaningA diagnostic approach using more than one testing modality
    Acceptable approachesGDH plus toxin; GDH plus toxin arbitrated by NAAT; or NAAT plus toxin
    PurposeImproves diagnostic accuracy and helps distinguish active C. difficile infection from colonization
    Definitions
    Diagnostic limitationDetection or non-detection of a microorganism does not necessarily establish a diagnosis
    Reporting limitationSome assays report organisms only at the genus level and cannot differentiate species
    Clinical interpretationAdditional clinical information is required, and some assays cannot distinguish pathogenic from nonpathogenic strains
    Definitions
    MeaningTests that detect bacterial, viral, or parasitic genetic material
    ExamplesNucleic acid amplification tests and multiplex molecular panels
    PerformanceGenerally provide more sensitive and rapid detection than culture
    Definitions
    MeaningA test developed and performed in-house by a laboratory
    RegulationRegulated by CMS as a high-complexity test under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88)
    FDA statusFDA clearance or approval is not currently required for clinical use
    Definitions
    Adult symptomsFever, chills, fatigue, cough, rhinorrhea, anorexia, pharyngitis, vomiting, new ageusia or anosmia, headaches, myalgia, diarrhea, and weakness
    Additional findings in individuals younger than 18May include irritability, decreased activity, nausea, rash, stomach pain, tachypnea, wheezing, dehydration, cyanosis, apnea, or refusal to eat
    Infant presentationsPoor feeding, lethargy, and fussiness may present instead of clear localizing symptoms

    Repeat C. difficile testing within seven days and testing for cure do not meet the policy's testing recommendations. Testing should be limited to symptomatic individuals and use a multistep approach incorporating a sensitive modality and a specific toxin test.

    For situations not otherwise described as covered, respiratory antigen or multiplex PCR panel testing that evaluates 6 or more respiratory pathogens does not meet coverage criteria.

    Routine broad respiratory panel testing is not covered when the individual does not have a qualifying respiratory infection presentation or when the result is not expected to influence management. Covered testing is limited to the situations and panel sizes described in the policy.

    Molecular panels for urine-based urinary tract infection testing, wound infection, joint infection, or general microorganism screening do not meet coverage criteria. Molecular pathogen panels performed on blood or cerebrospinal fluid are also excluded.

    Testing with limited clinical utility is not covered when the likely illness is uncomplicated viral gastroenteritis in an immunocompetent individual and the result is unlikely to change clinical management. Broad panels may also identify organisms of uncertain clinical significance.

    Excluded molecular pathogen panel applications include testing of 12 or more gastrointestinal pathogens, testing of 6 or more respiratory pathogens outside a qualifying situation, cerebrospinal fluid or blood pathogen panels, urine panels for urinary tract infection, wound or joint infection panels, and general microorganism screening.

    Additional excluded situations include routine testing for short-duration or self-limited gastrointestinal illness without relevant risk factors, repeat C. difficile testing within seven days, testing for C. difficile cure, and testing of formed stool or asymptomatic individuals.

    Molecular-based panel testing to screen for or diagnose joint infections does not meet coverage criteria, including testing with the BIOFIRE Joint Infection Panel or Synovasure Comprehensive PJI Test Panel with SynTuition.

    Outside the covered situations described in the policy, antigen or multiplex PCR-based respiratory panel testing of 6 or more pathogens does not meet coverage criteria. Symptomatic individuals may qualify for panels of up to 5 pathogens, and symptomatic immunocompromised individuals may qualify for multiplex PCR panels of up to 25 pathogens.